- Home
- UPB vs ARVN Comparison
UPB vs ARVN Comparison
Compare UPB & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UPB
- ARVN
- Stock Information
- Founded
- UPB 2021
- ARVN 2015
- Country
- UPB United States
- ARVN United States
- Employees
- UPB N/A
- ARVN N/A
- Industry
- UPB
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- UPB
- ARVN Health Care
- Exchange
- UPB NYSE
- ARVN Nasdaq
- Market Cap
- UPB 521.3M
- ARVN 456.2M
- IPO Year
- UPB 2024
- ARVN 2018
- Fundamental
- Price
- UPB $10.93
- ARVN $7.74
- Analyst Decision
- UPB Strong Buy
- ARVN Buy
- Analyst Count
- UPB 4
- ARVN 21
- Target Price
- UPB $56.50
- ARVN $20.53
- AVG Volume (30 Days)
- UPB 411.4K
- ARVN 2.2M
- Earning Date
- UPB 08-14-2025
- ARVN 07-29-2025
- Dividend Yield
- UPB N/A
- ARVN N/A
- EPS Growth
- UPB N/A
- ARVN N/A
- EPS
- UPB N/A
- ARVN N/A
- Revenue
- UPB $2,296,000.00
- ARVN $426,900,000.00
- Revenue This Year
- UPB N/A
- ARVN $4.26
- Revenue Next Year
- UPB N/A
- ARVN N/A
- P/E Ratio
- UPB N/A
- ARVN N/A
- Revenue Growth
- UPB N/A
- ARVN 498.74
- 52 Week Low
- UPB $5.14
- ARVN $5.90
- 52 Week High
- UPB $29.46
- ARVN $34.11
- Technical
- Relative Strength Index (RSI)
- UPB N/A
- ARVN 56.81
- Support Level
- UPB N/A
- ARVN $7.09
- Resistance Level
- UPB N/A
- ARVN $7.89
- Average True Range (ATR)
- UPB 0.00
- ARVN 0.39
- MACD
- UPB 0.00
- ARVN 0.06
- Stochastic Oscillator
- UPB 0.00
- ARVN 58.82
About UPB UPSTREAM BIO INC
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.